Clinical trial · Observational
The Association of Microbiota Composition With cGVHD After Allo-HSCT
The Association of Microbiota Composition With Chronic Graft Versus Host Disease
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Previous studies had found that the microbe in intestinal after allogeneic hematopoietic cell transplantation(allo-HSCT) were closely associated with overall survival and post-transplantation complications, especially graft versus host disease (GVHD).Due to the limited data on the association of microbiota composition with chronic GVHD(cGVHD) after allogeneic hematopoietic stem cell transplantation, the relationship between microbiota composition and post-transplantation complications, especially cGVHD, needs to be further evaluated.Detailed studies of the microbiome and host immune system will lead to the discovery of microbiome markers for early identification of patients at high risk for cGVHD. This may regulate patients' gut microbiota in an individualized manner to achieve optimal treatment outcomes while avoiding severe post-transplant cGVHD. We will operate a prospective, multicenter, nonrandomized, observational study. Patients will be asked to provide blood and stool samples during allo-HSCT.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Graft-versus-host-disease | — | UNRESOLVED | — |
| Complication | — | UNRESOLVED | — |
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Hematopoietic Stem Cell Transplantation | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood sample | Other | — | UNRESOLVED |
| stool sample | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- observational group
- description
- Patients with hematologic malignancies following allogeneic hematopoietic stem cell transplantation treatment
- interventionNames
- Other: blood sample
- Other: stool sample
- label
- control group
- description
- health control group: healthy volunteers
- interventionNames
- Other: blood sample
- Other: stool sample
Primary outcomes (1)
- measure
- Microbial changes in stool as measured by 16S rRNA gene sequencing in hematological cancer patients before, at time and after hematopoietic cell transplantation
- timeFrame
- 100 days
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: 1. aged between 18 years and 65 years 2. patients planned to be treated by allogeneic hematopoietic cell transplantation 3. signed written informed consent Exclusion Criteria: patients not-matching inclusion criteria
References
Publications (0)
Data not yet available